SIGA Technologies Inc (SIGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SIGA Technologies Inc (SIGA) has a cash flow conversion efficiency ratio of -0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.86 Million) by net assets ($198.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SIGA Technologies Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how SIGA Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SIGA Technologies Inc total liabilities for a breakdown of total debt and financial obligations.
SIGA Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SIGA Technologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GreenTech Environmental Co Ltd
SHG:688466
|
0.038x |
|
STL Technology Co Ltd
TWO:4931
|
0.035x |
|
Los Andes Copper Limited
V:LA
|
-0.006x |
|
MCNEX Co. Ltd
KQ:097520
|
0.085x |
|
Sesoda Corp
TW:1708
|
0.048x |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
-0.011x |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IS:SNGYO
|
-0.005x |
|
Vivien Corp
KO:002070
|
-0.043x |
Annual Cash Flow Conversion Efficiency for SIGA Technologies Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of SIGA Technologies Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see SIGA Technologies Inc (SIGA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $198.82 Million | $48.76 Million | 0.245x | +8.54% |
| 2024-12-31 | $215.80 Million | $48.76 Million | 0.226x | -53.08% |
| 2023-12-31 | $196.86 Million | $94.80 Million | 0.482x | +96.92% |
| 2022-12-31 | $170.16 Million | $41.61 Million | 0.245x | +270.84% |
| 2021-12-31 | $174.31 Million | $11.49 Million | 0.066x | -88.03% |
| 2020-12-31 | $129.79 Million | $71.52 Million | 0.551x | +395.98% |
| 2019-12-31 | $97.78 Million | $-18.20 Million | -0.186x | -127.82% |
| 2018-12-31 | $102.91 Million | $68.87 Million | 0.669x | +2550.63% |
| 2017-12-31 | $-323.14 Million | $-8.16 Million | 0.025x | -93.72% |
| 2016-12-31 | $-287.42 Million | $-115.59 Million | 0.402x | +1129.66% |
| 2015-12-31 | $-284.43 Million | $11.11 Million | -0.039x | +32.08% |
| 2014-12-31 | $-246.50 Million | $14.18 Million | -0.058x | -101.67% |
| 2013-12-31 | $16.98 Million | $58.44 Million | 3.442x | +592.75% |
| 2012-12-31 | $28.95 Million | $-20.22 Million | -0.699x | -213.88% |
| 2011-12-31 | $41.69 Million | $25.57 Million | 0.613x | +168.40% |
| 2010-12-31 | $12.07 Million | $-10.83 Million | -0.897x | -11.06% |
| 2009-12-31 | $10.49 Million | $-8.47 Million | -0.808x | +82.56% |
| 2008-12-31 | $1.55 Million | $-7.20 Million | -4.630x | -344.34% |
| 2007-12-31 | $5.23 Million | $-5.45 Million | -1.042x | -70.97% |
| 2006-12-31 | $7.28 Million | $-4.44 Million | -0.609x | -41.42% |
| 2005-12-31 | $3.23 Million | $-1.39 Million | -0.431x | +59.82% |
| 2004-12-31 | $4.56 Million | $-4.89 Million | -1.073x | -11.66% |
| 2003-12-31 | $5.55 Million | $-5.33 Million | -0.961x | +21.18% |
| 2002-12-31 | $2.17 Million | $-2.65 Million | -1.219x | -46.58% |
| 2001-12-31 | $3.54 Million | $-2.94 Million | -0.831x | +80.48% |
| 2000-12-31 | $924.74K | $-3.94 Million | -4.259x | -202.25% |
| 1999-12-31 | $2.20 Million | $-3.10 Million | -1.409x | -67.89% |
| 1998-12-31 | $5.60 Million | $-4.70 Million | -0.839x | -456.03% |
| 1997-12-31 | $10.60 Million | $-1.60 Million | -0.151x | +97.12% |
| 1996-12-31 | $400.00K | $-2.10 Million | -5.250x | -- |
About SIGA Technologies Inc
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.